`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`WATION LABORATORIES, INC.
`
`
`
`Scanned by CamScanner
`
`UNITED THERAPEUTICS, EX. 2026
`WATSON LABORATORIES V‘ UNITED THERAPEUTICS. IPR2017-01622
`Page 1 of 5
`
`
`
`""W' ’ “W "
`
`Declnrntion of Dr. llomin A. (ihnl'rnni
`
`1. ltr. Hussein A. (ihoihtni. hereby declare as follows:
`
`I.
`
`I em a member of Univeuity of(liean and Msrburg Lung Center
`
`t“UGMLC“). I rosemh center It the University Hospital Giossen studyins
`
`pulmonuy hypertension.
`
`1.
`
`i no not I plld consultant for United Therapeutics Corporation. which
`
`‘ “MW! 1! the mime or US. Patent No. 9.339.507. in connection with
`
`mam-7mm.
`
`3-.
`
`lint-00m ofthe German Immune article: Hussein Ardcachir
`
`Ghofi'lni. not; “NoiseWWW in do: Behandlung tier puimonalaflerieilen
`
`Hype-mete,“ Has. 30, 4 (June 2005): 296-302 (“the Ghofrsni article").
`
`I
`
`mallet Willa: “hesitation. Inc. (“Wntson”) submitted on English
`
`W mutation ofthis article in this proceeding as Exhibit 1005. which 1 have
`
`_ Q91.
`1 hive-W in the use of phosphodiesterase inhibitors for
` "hypertension. Therefore. I was eskedby Dr. Werner
`
`Sugatodrofimmdeeidnfiedthemtion oftbeGhofnni article relatingto
`
`i
`
`phosphodimiohibitom Ianhibitloosnhisuefionbegmsstthebottomof
`
`I msflmwws n.5mmdldmjohulydrafiedthe
`.,_,
`=
`1.1.
`n.
`..
`
`
`
`Scanned by CamScanner
`
`UNITED THERAPEUTICS. EX. 2026
`WATSON LABORATORIES V‘ UNITED THERAPEUTICS. IPR2017-01622
`Page 2 of 5
`
`
`
`IPRZO]7-01622
`
`Declatmion of Dr. Hussein A. Ghofm
`
`\
`
`sections on vasomfive therapy, inhaled ilopmst, combination therapies, and
`
`manufem'ly fomsofueatmmtofpulmonmyhypatmsiomaswellasthe
`
`introduction. InfinewithmenormalpmmicemflnUGMCm'chcemerJ
`
`wasincludedasflaefirstunhormtheGhofi-ani article formmesignifim
`
`cont-lbw
`
`Ididnotmakemamialomihtfiomtoanyoflaersectionofthe
`S.
`_ M'“
`w ~
`.
`
`Wafilmfifiaflyfidmm'hnemflnfolbw'mgm
`
`Wmhmmmmfimdm
`
`WkflnMwflnfimofflnpuhmwymflr
`
`moving. hflfisfintsmdy, l7patieaflswifl15evempre—
`
`mus-w).- .m-um ninja mutation in
`
`ofantimof>180mh hmmmmm
`
`WWMam-pmymvhymmm
`
`amnmfiomwwnmmfimm
`W '..' mmmmme
`
`a 3km”
`MI I' oflflifllfl'm‘ i n. 'I'I II'
`maflMmhmhhpflm
`_
`.
`
`
`._'f_:unb§Mh<llikl _
`
`
`
`Scanned by CamScanner
`
`UNITED THERAPEUTICS. EX. 2026
`WATSON LABORATORIES V. UNITED THERAPEUTICS. IPR201?-01622
`Page 3 of5
`
`
`
`II‘RMII 'HHOJ.‘
`
`Declamllun (If Dr. lluascln A. (“10me
`
`'I‘Ise Int‘mnmlon In lhI
`
`Voswinekel and Dr. Werner Seenet end the Idea to perform the underlying work
`
`minted wIth mom.
`
`6.
`
`The section ofthe Ghofi-eni article relating to selective endothelin A
`Friedrich Grimmer and Dr. Frank
`recap wonlau we: dnfted by Dr.
`.
`In Exhibit 1005, this section
`W
`Reiehenberaer; both having experience In this field.
`
`
`
`
`
`Scanned by CamScanner
`
`UNITED THERAPEUTICS. EX. 2026
`WATSON LABORATORIES V. UNITED THERAPEUTICS. IPR2017-O1622
`Page 4 of 5
`
`
`
`II‘RZOI 7-0l622
`
`Declaration of Dr. llossein A. Ghofmni
`
`I hereby declare that all statements made herein of my knowledge are true
`7
`and that all statements made on informanon and beltefare believed to be true an
`
`.
`
`.
`
`.
`
`;
`
`d
`
`that willful false
`
`taternents andthe like so made we punishable by fine or imprisonment, or both
`nder Section 1001 ofTitle 18 ofthe United States Code.
`
`s u
`
`Date-.ll" 06'!"
`
`,‘20-17
`
`
`
`Scanned by CamScanner
`
`UNITED THERAPEUTICS. EX. 2026
`WATSON LABORATORIES V‘ UNITED THERAPEUTiCS. IPR2017-01622
`Page 5 of 5
`
`